Hormone therapy impairs endothelial function in postmenopausal women with type 2 diabetes mellitus treated with rosiglitazone

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 9, 2004, Pages 4615-4619

  Honisett, Suzy Y ^a,b   Stojanovska, Lily ^a   Sudhir, Krishnankutty ^b   Kingwell, Bronwyn A ^b   Dawood, Tye ^b   Komesaroff, Paul A ^b,c  

^a VICTORIA UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GLUCOSE; LIPID; PROGESTERONE; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLYCEMIC LOAD; HEART PROTECTION; HORMONAL THERAPY; HUMAN; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

AGED; BLOOD PRESSURE; CORONARY DISEASE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 4544282223     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031414     Document Type: Article

References (44)

1. Fonseca V, Rosenstock J, Patwardhan R, Salzman A 2000 Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283:1695-1702
2. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI 2000 Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43:278-284
3. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI 2001 Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86:280-288
4. 2000 Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342:381-389
5. Zhang HY, Reddy SR, Kotchen TA 1994 Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension 24:106-110
6. Lim SC, Caballero AE, Arora S, Smakowski P, Bashoff EM, Brown FM, Logerfo FW, Horton ES, Veves A 1999 The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes. J Clin Endocrinol Metab 84:4159-4164
7. Waddell TK, Rajkumar C, Cameron JD, Jennings GL, Dart AM, Kingwell BA 1999 Withdrawal of hormonal therapy for 4 weeks decreases arterial compliance in postmenopausal women. J Hypertens 17:413-418
8. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH 1991 Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 325:756-762
9. Stampfer MJ, Colditz GA 1991 Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 20:47-63
10. Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Lithell H, Mohsen R, Naessen T 1992 The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 99:821-828
11. Ettinger B, Friedman GD, Bush T, Quesenberry Jr CP 1996 Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87:6-12
12. Friday KE, Dong C, Fontenot RU 2001 Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 86:48-52
13. Ferrara A, Karter AJ, Ackerson LM, Liu JY, Selby JV 2001 Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: the Northern California Kaiser Permanente diabetes registry. Diabetes Care 24:1144-1150
14. Brussaard HE, Gevers Leuven JA, Frolich M, Kluft C, Krans HM 1997 Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 40:843-849
15. Andersson B, Mattsson LA, Hahn L, Marin P, Lapidus L, Holm G, Bengtsson BA, Bjorntorp P 1997 Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:638-643
16. Sowers JR 1997 Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 29:690-699
17. Ling S, Little PJ, Williams MRI, Dau A, Hashimura K, Lui JP, Komesaroff PA, Sudhir K 2002 High glucose abolishes the antiproliferative effect of 17β oestradiol in human vascular smooth muscle cells. Am J Physiol Endocrinol Metab 282:E746-E751
18. Bolego C, Cignarella A, Zancan V, Pinna C, Zanardo R, Puglisi L 1999 Diabetes abolishes the vascular protective effects of estrogen in female rats. Life Sci 64:741-749
19. Saltevo J, Puolakka J, Ylikorkala O 2000 Plasma endothelin in postmenopausal women with type 2 diabetes mellitus and metabolic syndrome: a comparison of oral combined and transdermal oestrogen-only replacement therapy. Diabetes Obes Metab 2:293-298
20. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE 1992 Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-1115
21. Liu Z, Brin KP, Yin FC 1986 Estimation of total arterial compliance: an improved method and evaluation of current methods. Am J Physiol 251:H588-H600
22. Cameron JD, Dart AM 1994 Exercise training increases total systemic arterial compliance in humans. Am J Physiol 266:H693-H701
23. Chen S, Noguchi Y, Izumida T, Tatebe J, Katayama S 1996 A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J Hypertens 14:1325-1330
24. Ludbrook J 1998 Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 25:1032-1037
25. Barrett-Connor E, Cohn BA, Wingard DL, Edelstein S 1991 Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 265:627-631
26. Ma H, Sprecher HW, Kolattukudy PE 1998 Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARγ-expressing tissue. J Biol Chem 273:30131-30138
27. Keller H, Givel F, Perroud M, Wahli W 1995 Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol 9:794-804
28. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM 1995 A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83:813-819
29. Ham EA, Cirillo VJ, Zanetti ME, Kuehl Jr FA 1975 Estrogen-directed synthesis of specific prostaglandins in uterus. Proc Natl Acad Sci USA 72:1420-1424
30. Tawfik OW, Huet YM, Malathy PV, Johnson DC, Dey SK 1987 Release of prostaglandins and leukotrienes from the rat uterus is an early estrogenic response. Prostaglandins 34:805-815
31. Wilson Jr L, Huang LS 1984 Temporal response of uterine prostaglandins to estradiol treatment in the ovariectomized-pregnant rat. Prostaglandins 28:103-110
32. Pakrasi PL, Dey SK, Johnson DC 1984 Studies on the temporal pattern of prostaglandin synthesis in the uterus of the delayed implanting rat with or without implantation inducing stimuli. Prostaglandins Leukot Med 14:365-381
33. Chaud M, Faletti A, Beron de Estrada M, Gimeno AL, Gimeno MA 1994 Synthesis and release of prostaglandins D2 and E2 by rat uterine tissue throughout the sex cycle. Effects of 17β-estradiol and progesterone. Prostaglandins Leukot Essent Fatty Acids 51:47-50
34. Freyberger A, Degen GH 1989 Studies on the stoichiometry of estrogen oxidation catalyzed by purified prostaglandin-H-synthase holoenzyme. J Steroid Biochem 33:473-481
35. Fayard JM, Chanal S, Felouati B, Macovschi O, Lagarde M, Pageaux JF, Laugier C 1994 Regulation of quail oviduct phospholipase A2 activity by estradiol. Eur J Endocrinol 131:205-212
36. Miyamoto T, Kaneko A, Kakizawa T, Yajima H, Kamijo K, Sekine R, Hiramatsu K, Nishii Y, Hashimoto T, Hashizume K 1997 Inhibition of peroxisome proliferator signaling pathways by thyroid hormone receptor. Competitive binding to the response element. J Biol Chem 272:7752-7758
37. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF 1995 Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91:1314-1319
38. Takase B, Uehata A, Akima T, Nagai T, Nishoika T, Hamabe A, Satomura K, Ohsuzu F, Kurita A 1998 Endothelium-dependent flow-mediated vasodilatation coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 82:1535-1539
39. Ling S, Little PJ, Williams MRI, Dai A, Hashimura K, Liu JP, Komesaroff PA, Sudhir K 2002 High glucose abolishes the antiproliferative effect of 17β estradiol in human vascular smooth muscle cells via protein kinase c-β: implications for vascular disease in diabetes mellitus. Am J Physiol 282:E746-E751
40. Neunteufl T, Katzenschlagei R, Hassan A, Klaar U, Schwarzacher S, Glogar D, Bauer P, Weidinger F 1997 Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 129:111-118
41. The Writing Group for the PEPI Trial 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273:199-208
42. Crook D, Godsland IF, Hull J, Stevenson JC 1997 Hormone replacement therapy with dydrogesterone and 17β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow-up. Br J Obstet Gynaecol 104:298-304
43. Heikkinen J, Kyllonen E, Kurttila-Matero E, Wilen-Rosenqvist G, Lankinen KS, Rita H, Vaananen HK 1997 HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women. Maturitas 26:139-149
44. Nabulsi A, Folsom A, White A, Patsch W, Heiss G, Wu K, Szklo M 1993 Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 328:1069-1075